2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.58: Impact of Molecular Profiling on Clinical Management of LATAM Cancer Patients: Insights From a Next Generation Sequencing and Immunohistochemistry Panel

PP01.58: Impact of Molecular Profiling on Clinical Management of LATAM Cancer Patients: Insights From a Next Generation Sequencing and Immunohistochemistry Panel

Back to course

Pdf Summary

The study, titled "Impact of molecular profiling on clinical management of LATAM cancer patients: Insights from a next generation sequencing and immunohistochemistry panel," investigates the influence of molecular profiling on treatment decisions for cancer patients in LATAM using a comprehensive panel called Optimus. This study addresses the challenges of tumor biopsy profiling in LATAM due to economic constraints and limited evidence applicability.<br /><br />The research analyzed tumor tissue samples from 811 patients using next-generation sequencing (NGS) with the Oncomine Focus Assay (OFA) and assessed PD-L1 and MMR (mismatch repair) protein expression. Of these, 652 samples met the quality criteria for DNA and RNA. The Optimus panel identified clinically relevant genetic alterations in 72% of patients, MMR protein deficiency in 2%, and PD-L1 positivity in 48.6%. Key findings highlighted the mutual exclusivity and co-occurrence of certain genetic mutations like KRAS and BRAF, with those like EGFR, CTNNB1, and others.<br /><br />Notably, the molecular profiling contributed to the clinical management of 66% of patients, aiding in treatment decisions for 77% of those cases. The study concluded by demonstrating improved treatment responses in patients when the Optimus panel informed their clinical management.<br /><br />The analysis revealed significant gene mutation patterns across different tumor types, with higher frequencies of KRAS, EGFR, and PIK3CA mutations. It also correlated PD-L1 positivity with mutations in KRAS and BRAF, while the absence of PD-L1 expression linked to CTNNB1 mutations.<br /><br />Overall, the study underscores the significance of molecular profiling in enhancing decision-making and treatment outcomes, offering valuable insights into the cancer genomic landscape in LATAM regions. This could pave the way for more individualized and effective therapeutic strategies in oncological care.

Asset Subtitle

Manuel Fernandez Bibiloni

Keywords

molecular profiling

LATAM cancer patients

next generation sequencing

immunohistochemistry

Optimus panel

tumor biopsy challenges

KRAS mutations

PD-L1 expression

clinical management

genomic landscape